U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459959) titled 'LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response' on March 04.
Brief Summary: The goal of this clinical trial is to assess feasibility, safety, tolerability, and central nervous system target engagement of oral lithium orotate in adults with biomarker-confirmed early Alzheimer's disease. The main questions it aims to answer are:
* Can participants be recruited, retained, and remain adherent (target >=80%) over 9 weeks of treatment, and what is the frequency and severity of adverse events?
* Does lithium orotate increase cerebrospinal fluid (CSF) lithium concentration from base...